NLE Oncology Nursing — Cancer Treatment Modalities and Nursing CareSummary

Chemotherapy uses cytotoxic drugs administered systemically (via bloodstream) to kill rapidly dividing cancer cells throughout the body. Chemotherapeutic agents are classified as cell-cycle-specific drugs (acting during particular phases such as S phase for methotrexate or M phase for vincristine) or cell-cycle-nonspecific drugs (acting in any phase, including resting cells, such as alkylating agents like cyclophosphamide). This systemic distribution explains both the therapeutic benefit (reaching cancer anywhere in the body) and the major toxicity profile (damaging normal fast-dividing tissues, particularly the bone marrow, gastrointestinal mucosa, and hair follicles).

Bone marrow suppression (myelosuppression) is the most serious and dose-limiting toxicity of chemotherapy. It lowers all three blood cell lines: neutrophils (causing neutropenia and life-threatening infection), platelets (causing thrombocytopenia and bleeding), and red blood cells (causing anemia and fatigue). The nadir is the point of lowest blood counts, typically occurring 7 to 14 days after chemotherapy administration. The patient is most vulnerable to infection and bleeding at the nadir. Absolute neutrophil count (ANC) is the key monitoring parameter: ANC below 1,000/mm³ indicates neutropenia with increased infection risk; ANC below 500/mm³ indicates severe neutropenia requiring strict precautions. Neutropenic precautions include meticulous hand hygiene, private room placement, visitor restrictions (excluding anyone ill), avoiding fresh flowers and standing water, a low-bacteria diet (avoiding raw fruits, vegetables, and undercooked foods), minimizing invasive procedures, and close temperature monitoring. Granulocyte colony-stimulating factors (filgrastim) may be administered to accelerate neutrophil recovery.

Major chemotherapy toxicities beyond myelosuppression include: (1) Nausea and vomiting—among the most common and distressing; managed by giving antiemetics prophylactically before chemotherapy (5-HT3 antagonists like ondansetron, substance-P blockers like aprepitant, and dexamethasone), continuing them around the clock during treatment, offering small bland meals, and monitoring hydration and electrolytes. (2) Alopecia (hair loss)—distressing but temporary; hair regrows after treatment, sometimes with different texture or color; nursing care focuses on preparing patients in advance and suggesting wigs, scarves, or caps as body-image support. (3) Stomatitis/mucositis—painful inflammation of oral mucosa managed with frequent gentle oral care using soft toothbrush, saline or bland rinses, topical anesthetics, avoiding alcohol-based mouthwashes, and avoiding hot, spicy, and acidic foods. (4) Fatigue—the most commonly reported symptom; intervention focuses on teaching energy conservation and adequate rest. (5) Diarrhea and constipation—managed through diet modifications, fluid intake, and medications; note that vinca alkaloids like vincristine cause both constipation and neuropathy as specific side effects.

Extravasation is the leakage of a vesicant (tissue-damaging) chemotherapy drug out of the vein into surrounding subcutaneous tissue, potentially causing severe tissue damage, blistering, and necrosis. Vesicant drugs include doxorubicin and vincristine. Prevention is the priority: verify blood return and vein patency before and during infusion; use a central line for known vesicants when possible. If extravasation occurs, it is a nursing emergency requiring immediate action: STOP the infusion immediately (but do not remove the needle right away); leave the needle in place to aspirate residual drug from the tissue; follow protocol for the specific agent (apply cold or warm compresses as indicated, administer the specific antidote if one exists); elevate the extremity; and notify the provider. Thorough documentation of the site, appearance, and interventions is mandatory. Early recognition and action prevent permanent tissue damage.

Chemotherapy drugs are hazardous to healthcare workers who handle them—they are mutagenic (can cause genetic damage), teratogenic (can harm fetal development), and carcinogenic (can cause cancer). Safe handling is a professional and occupational safety responsibility. Requirements include: wearing personal protective equipment (PPE)—chemotherapy-rated gloves (often double-gloved), a gown, and eye protection; using a biological safety cabinet for drug preparation; pregnant nurses should avoid handling chemotherapy and should not care for patients with internal radioactive sources due to fetal exposure risks; disposing of all drugs, tubing, and contaminated materials in designated cytotoxic (hazardous) waste containers; treating the patient's body fluids as hazardous for approximately 48 hours after chemotherapy administration and using appropriate precautions when handling them; and following spill-kit procedures for any medication spill. These practices protect the nurse, other healthcare workers, and the environment.

Radiation therapy uses high-energy ionizing radiation to destroy cancer cell DNA within a targeted area. It is a local treatment—side effects are confined to the irradiated area. External beam radiation (teletherapy) delivers radiation from a machine outside the body; the patient is NOT radioactive after treatment and poses NO risk to others. Skin markings are placed to aim the beam precisely and must be preserved throughout treatment. Internal radiation (brachytherapy) places a radioactive source inside or next to the tumor (for example, a sealed implant for cervical or endometrial cancer). While a sealed source is in place, the patient emits radiation and IS a source of exposure to nearby people; healthcare workers, visitors, and others must maintain distance and shielding. With unsealed radioactive sources (such as radioactive iodine for thyroid cancer), the patient's body fluids may be radioactive.

Radiation therapy causes radiodermatitis—redness, dryness, and irritation in the treatment field. Nursing teaching emphasizes: (1) Do NOT wash off the radiation markings that target the beam, as losing these markings requires remarking and affects treatment precision. (2) Wash the irradiated area gently with lukewarm water and mild soap; pat dry. (3) Do NOT apply lotions, powders, creams, perfumes, or deodorants to the treatment area unless prescribed, because these products can contain metals (which alter radiation dose) or increase skin irritation. (4) Avoid direct sunlight, extreme heat or cold (no heating pads or ice packs), and tight or abrasive clothing over the site; wear soft cotton. (5) Do not scratch or rub the area, as this worsens irritation. These measures minimize radiodermatitis and maintain treatment accuracy.

When caring for a patient with an internal radioactive source, nurses protect themselves, other staff, and visitors using three fundamental principles of radiation protection: (1) Time—minimize time spent near the patient; organize and cluster care to be efficient, reducing cumulative exposure. (2) Distance—maximize physical distance from the radioactive source; radiation intensity falls sharply with increasing distance (inverse square law principle). (3) Shielding—use lead shielding as appropriate (lead aprons, lead-lined containers). Additional precautions for a sealed internal implant include: assigning the patient a private room to limit exposure to others; wearing a radiation dosimeter (film badge) to monitor cumulative exposure; restricting pregnant nurses and children from the room and from caregiving due to fetal/pediatric radiosensitivity; keeping a lead-lined container and long forceps in the room in case the implant becomes dislodged; and NEVER touching a dislodged source with bare hands—use forceps to pick it up and place it in the lead container immediately, then notify the provider. Rotating staff assignments limits any one nurse's exposure. These practices ensure occupational safety and compliance with radiation protection regulations.

Surgery serves multiple roles in cancer care: (1) Diagnostic—biopsy to obtain tissue for histologic diagnosis and staging. (2) Curative—removing localized cancer completely with the goal of cure. (3) Debulking—reducing tumor size to improve efficacy of other therapies like chemotherapy or radiation. (4) Palliative—relieving symptoms caused by the tumor, such as obstruction or pain. (5) Preventive/prophylactic—removing high-risk tissue before it becomes malignant (for example, prophylactic mastectomy in BRCA-positive women). (6) Reconstruction—restoring function and body image after tumor removal. Nursing care for cancer surgery follows general perioperative principles (preoperative assessment, preparation, intraoperative support, postoperative monitoring) but requires special attention to the patient's overall condition, which may be compromised by the cancer itself and prior treatments (chemotherapy, radiation). This requires careful assessment of functional status, nutritional status, organ function, and treatment history.

Newer cancer therapies act more selectively than traditional chemotherapy. Targeted therapy attacks specific molecules expressed on cancer cells. Examples include: monoclonal antibodies—trastuzumab (for HER2-positive breast cancer; requires cardiac function monitoring due to cardiotoxicity) and rituximab (for lymphoma; watch for infusion reactions); and tyrosine kinase inhibitors—imatinib. Immunotherapy stimulates the patient's own immune system to recognize and fight cancer. Examples include: interferons and interleukins (which cause flu-like symptoms as side effects); and immune checkpoint inhibitors (which can cause autoimmune and inflammatory side effects in any organ system—the most severe being immune-related adverse events, irAEs, affecting lungs, liver, kidney, skin, GI tract, and endocrine organs). Nursing care centers on monitoring for infusion reactions and hypersensitivity reactions (give first doses slowly with emergency equipment readily available); teaching about specific drug side effects; and recognizing autoimmune manifestations early. These agents have different toxicity profiles than traditional chemotherapy, requiring different monitoring parameters and patient education.

A fever in a neutropenic patient (ANC below 500/mm³) is a medical emergency because it may represent overwhelming infection. A temperature of approximately 38.3°C once, or 38.0°C sustained for one hour, in a severely neutropenic patient may be the only sign of serious infection—the patient cannot mount a normal inflammatory response, so there is no pus, minimal local signs, and minimal systemic signs. Immediate action is required: obtain blood cultures and start broad-spectrum antibiotics within one hour of fever detection; do not wait for culture results. Do not give antipyretics before cultures unless specifically ordered, and never give aspirin. Close monitoring of vital signs, blood glucose, renal function, and mental status is essential. Delays in antibiotic initiation significantly increase mortality risk. This represents the most time-sensitive oncologic emergency.

Tumor lysis syndrome (TLS) is a life-threatening metabolic emergency occurring when a large number of tumor cells are destroyed rapidly—usually shortly after starting chemotherapy for bulky, treatment-sensitive cancers such as acute leukemia and lymphoma. As tumor cells break down, they spill their intracellular contents into the bloodstream, causing: hyperkalemia (high potassium—dangerous for cardiac rhythm), hyperphosphatemia (high phosphate—causes secondary hypocalcemia), hyperuricemia (high uric acid from nucleic acid breakdown—precipitates in renal tubules causing acute kidney injury), and hypocalcemia (low calcium from hyperphosphatemia and precipitation). The clinical result can be acute kidney injury and fatal cardiac arrhythmias. Prevention and management include: aggressive IV hydration (to flush uric acid and prevent kidney precipitation); allopurinol (xanthine oxidase inhibitor) or rasburicase (urate oxidase—more rapid action) to lower uric acid levels; correction of electrolyte abnormalities; and continuous monitoring of renal function (BUN, creatinine) and cardiac rhythm (ECG). High-risk patients may receive prophylactic rasburicase before chemotherapy.

Superior vena cava (SVC) syndrome is compression or obstruction of the superior vena cava by a tumor (commonly lung cancer, lymphoma, or metastatic disease to mediastinal nodes), blocking venous return from the head and upper body to the heart. This creates a venous backup in the upper body. Classic signs include: facial and neck swelling (edema), bilateral upper extremity edema, distended neck and chest wall veins, dyspnea, chest pain, and a sensation of fullness or pressure in the head. The development may be acute or gradual. Management is to: elevate the head of the bed to 45 degrees or higher to reduce venous pressure in the head and neck; provide supplemental oxygen to manage dyspnea; and administer urgent radiation therapy or chemotherapy to shrink the tumor and relieve obstruction. Corticosteroids may be given to reduce inflammation. While SVC syndrome is serious, it is rarely immediately fatal, but the symptoms significantly impact quality of life and psychological status.

Spinal cord compression occurs when a tumor—usually a metastasis to the vertebral body or epidural space—presses on the spinal cord, threatening permanent neurologic damage. Because delay in diagnosis and treatment leads to irreversible paralysis, this is one of the most time-critical oncologic emergencies. The earliest and most common symptom is back pain—often the only symptom initially—followed by motor weakness (difficulty walking, weakness of the lower extremities), sensory loss (numbness or paresthesias, often in a dermatomal pattern), and changes in bowel or bladder function (urinary retention or incontinence, constipation). The progression from pain to paralysis can occur over hours to days. Any new or worsening back pain in a patient with known cancer must be reported immediately—this is a key nursing responsibility. Diagnosis is confirmed by MRI. Treatment includes high-dose corticosteroids (dexamethasone) to reduce spinal cord edema, plus radiation therapy or surgery to decompress the cord. Early treatment preserves neurologic function; delayed treatment results in permanent disability.

Hypercalcemia results from cancer-related mechanisms: bone metastasis causing osteolytic bone destruction and calcium release, or tumor secretion of parathyroid hormone-related protein (PTHrP) and vitamin D-like substances that increase serum calcium. Signs reflect the effects of hypercalcemia on the neuromuscular system and GI tract: fatigue and muscle weakness (due to muscle cell calcium imbalance), confusion and lethargy (from CNS calcium effects), nausea and anorexia, constipation (GI motility decreases with hypercalcemia), polyuria and polydipsia (due to calcium effects on renal tubules causing nephrogenic diabetes insipidus), and in severe hypercalcemia, cardiac arrhythmias and coma. The severity of symptoms correlates with both the absolute calcium level and the rate of rise. Management includes: aggressive IV hydration with normal saline (the most important intervention, promoting renal calcium excretion); bisphosphonates (such as zoledronic acid or pamidronate) to inhibit osteoclast bone resorption and lower calcium (effect takes 3–5 days); calcitonin (rapid but temporary calcium-lowering effect); and treatment of the underlying cancer. Loop diuretics may be used after adequate rehydration but are no longer a primary intervention. Monitoring of serum calcium, phosphate, albumin, renal function, and cardiac status is essential.